Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Hoyt-Miggelbrink A"'
Autor:
Peter E Fecci, Selena J Lorrey, Lucas P Wachsmuth, Jessica Waibl Polania, Alexandra Hoyt-Miggelbrink, John Finlay, Mackenzie Price, Corey Neff, Xiuyu Cui, Emily Lerner, Daniel Wilkinson, Kelly Hotchkiss, Ethan Srinivasan, Quinn T Ostrom
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/d766309243104e88828e0f8e00b604ca
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jessica Waibl Polania, Emily C. Lerner, Daniel S. Wilkinson, Alexandra Hoyt-Miggelbrink, Peter E. Fecci
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Successful cancer immunotherapies rely on a replete and functional immune compartment. Within the immune compartment, T cells are often the effector arm of immune-based strategies due to their potent cytotoxic capabilities. However, many tumors have
Externí odkaz:
https://doaj.org/article/808b5813dcf74fa597cb5e25097d8f85
Autor:
Selena J Lorrey, Jessica Waibl Polania, Lucas P Wachsmuth, Alexandra Hoyt-Miggelbrink, Zachariah P Tritz, Ryan Edwards, Delaney M Wolf, Aaron J Johnson, Peter E Fecci, Katayoun Ayasoufi
Publikováno v:
Neuro-Oncology Advances. 5
Background The nervous and immune systems interact in a reciprocal manner, both under physiologic and pathologic conditions. Literature spanning various CNS pathologies including brain tumors, stroke, traumatic brain injury and de-myelinating disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::266b431019e60c6167f6e212258c119f
https://doi.org/10.1093/noajnl/vdad035
https://doi.org/10.1093/noajnl/vdad035
Autor:
Emily Lerner, Alexandra Hoyt-Miggelbrink, Peter E. Fecci, Jessica Waibl Polania, Daniel Wilkinson
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
Frontiers in Immunology
Successful cancer immunotherapies rely on a replete and functional immune compartment. Within the immune compartment, T cells are often the effector arm of immune-based strategies due to their potent cytotoxic capabilities. However, many tumors have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::598ff21f4d78a1834e84aa783be58e21
https://www.frontiersin.org/articles/10.3389/fimmu.2021.777073/full
https://www.frontiersin.org/articles/10.3389/fimmu.2021.777073/full
Autor:
Lorrey, Selena J, Polania, Jessica Waibl, Wachsmuth, Lucas P, Hoyt-Miggelbrink, Alexandra, Tritz, Zachariah P, Edwards, Ryan, Wolf, Delaney M, Johnson, Aaron J, Fecci, Peter E, Ayasoufi, Katayoun
Publikováno v:
Neuro-Oncology Advances; 2023, Vol. 5 Issue 1, p1-11, 11p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Neuro-Oncology Advances. 4:i4-i4
Brain metastases affect nearly 20% of all cancer patients. Likewise, glioblastoma (GBM) is the most common primary brain cancer in adults and remains universally lethal. Current immunotherapeutic efficacy is hindered by immunosuppression present in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39b01141c739604c4ee294d3d944d2ef
https://doi.org/10.1093/noajnl/vdac078.014
https://doi.org/10.1093/noajnl/vdac078.014
Autor:
Peter E. Fecci, William Tomaszweski, Karolina Woroniecka, Jessica Waibl Polania, Alexandra Hoyt-Miggelbrink
Publikováno v:
Neuro-Oncology. 23:vi95-vi95
BACKGROUND Glioblastoma (GBM) is the most common primary brain cancer in adults and remains universally lethal. Median survival remains a bleak 15-17 months from time of diagnosis, and current immunotherapeutic efficacy continues to be hindered by th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20891cc05717a54c8fe5d4c8c10014d5
https://doi.org/10.1093/neuonc/noab196.374
https://doi.org/10.1093/neuonc/noab196.374
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.